Journals / Tüberküloz ve Toraks / 2009 / Cilt: 57 - Sayı: 4

Kronik obstrüktif akciğer hastalığı (KOAH) olan olgularda tiroid hormon ve somatomedin-C (IGF-1) düzeylerinin değerlendirilmesi ve hastalığın ağırlık derecesi ile ilişkisi

Evaluation of thyroid hormone levels and somatomedin-C (IGF-1) in patients with chronic obstructive pulmonary disease (COPD) and relation with the severity of the disease

Pages
369–375
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies with larger sample sizes are required to confirm our conclusions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic obstructive pulmonary disease (COPD) has recently become a significant cause of mortality and morbidity.
📊
Key Findings & Data:In the present study, we aimed to investigate the relationship between the severity of the disease and levels of serum thyroid hormones and somatomedin-C [Insulin-Like Growth Factor (IGF-1)].
💡
Conclusion & Impact:Further studies with larger sample sizes are required to confirm our conclusions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic obstructive pulmonary disease (COPD) has recently become a significant cause of mortality and morbidity. In the present study, we aimed to investigate the relationship between the severity of the disease and levels of serum thyroid hormones and somatomedin-C [Insulin-Like Growth Factor (IGF-1)]. Sixty one COPD cases (group 1) were enrolled. Control group (group 2) consisted of 20 healthy individuals. Blood samples were obtained for the analysis of arterial blood gases and hormone levels and respiratory function tests were performed on the same day. Measured hormone levels were compared between group 1 and group 2. Among thyroid hormone levels, there was no significant difference in thyroid stimulating hormone and free T3 between group 1 and 2 whereas free T4 levels were significantly higher in group 1 (p< 0.01). Additionally, mean IGF-1 levels were significantly lower in group 1 (p< 0.005). When three groups, classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, were compared, significant differences were observed between mild-moderate COPD cases and severe patients with respect to free T3 and IGF-1 levels (p< 0.05). Hormone levels in COPD patients change depending on the severity of the disease. In the future hormone therapies can use for the COPD treatments. Further studies with larger sample sizes are required to confirm our conclusions.

Özet

Kronik obstrüktif akciğer hastalığı (KOAH), yaygınlığından dolayı günümüzde önemli bir mortalite ve morbidite nedenidir. Araştırmamızda KOAH’lı olgularda serumda tiroid hormonlarının ve somatomedin-C [insülin benzeri büyüme faktörü (IGF-1)] düzeylerinin hastalığın ağırlık derecesi ile ilişkisini incelemeyi amaçladık. Çalışmaya 61 KOAH olgusu alındı. Kontrol grubunu; herhangi bir hastalığı bulunmayan 20 sağlıklı olgu oluşturdu. Olguların aynı gün içinde arteryel kan gazları ve hormon düzeyleri için kanları alınarak, solunum fonksiyon testleri yapıldı. Ölçülen hormon düzeyleri hasta grup (grup 1) ile kontrol grubu (grup 2) arasında karşılaştırıldı. Grup 1 ve grup 2 arasında tiroid hormon değerlerinden tiroid stimüle edici hormon ve serbest T3 düzeylerinde anlamlı fark bulunmazken, çalışma grubunda serbest T4 düzeyi istatistiksel olarak anlamlı yüksek saptandı (p< 0.01). IGF-1 ortalama değerleri grup 1’de istatistiksel olarak anlamlı düşük saptandı (p< 0.05). “Global Initiative for Chronic Obstructive Lung Disease (GOLD)” kriterlerine göre olgular üç gruba ayrılarak (hafif-orta, ağır, çok ağır) karşılaştırıldığında hafif-orta derecede KOAH’lı olgularla, çok ağır KOAH’lı olgular arasında serbest T3 ve IGF-1 düzeyleri arasında istatistiksel olarak anlamlı farklılık bulundu (p< 0.05). KOAH’lı olgularda hastalığın ağırlık derecesine göre hormon düzeylerinde değişiklikler olmaktadır. Gelecekte hormon replasman tedavilerinin KOAH’lı olguların tedavisinde yer alabileceği düşünülebilir. Bunu saptamak için daha geniş hasta gruplarının olduğu çalışmalara ihtiyaç vardır.

🔖

Cite This Article

KARADAĞ, M., EDİGER, D., EGE, E., COŞKUN, F., UZASLAN, E., GÖZÜ, O. (2022). Kronik obstrüktif akciğer hastalığı (KOAH) olan olgularda tiroid hormon ve somatomedin-C (IGF-1) düzeylerinin değerlendirilmesi ve hastalığın ağırlık derecesi ile ilişkisi. Tüberküloz ve Toraks, Cilt: 57 - Sayı: 4, 369–375. https://ajindex.com/articles/618905

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cherniack NS. Control of breathing in COPD. In: Cherniack NS (ed). Chronic Obstructive Pulmonary Disease. Philadelphia: WB Saunders Company, 1991: 117-26
  2. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(Suppl 46): 76-80
  3. Meek PM, Schwartzstein RM, Adams L, et al. Dyspnea, mechanisms, assessment, and management: A consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1995; 159: 321-40
  4. Schols AMWJ, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-24
  5. Pape GS, Friedman M, Underwood LE, Clemmons DR. The effects of growth hormone on weight gain and pulmonary function in patients with chronic obstructive pulmonary disease. Chest 1991; 99: 1495-500
  6. Burdet L, Muralt B, Schultz Y, et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997; 156: 1800-6
  7. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38
  8. Scalvini S, Volterrani M, Vitacca M, et al. Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996; 51: 380-6
  9. Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124: 83-9
  10. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-1. Thorax 2003; 58: 752-6
  11. Suchner U, Rothkopf MM, Stanislaus G, et al. Growth hormone and pulmonary disease. Metabolic effects in patients receiving parenteral nutrition. Arch Intern Med 1990; 150: 1225-30
  12. Iioka Y, Tatsumi K, Sugito K, et al. Effects of insulin-like growth factor on nitrogen balance during hypoxic exposure. Eur Respir J 2002; 20: 293-9
  13. Lewis MI, Horvitz GD, Clemmons DR, Fournier M. Role of IGF-1 and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. Am J Physiol Endocrinol Metab 2002; 282: 483-90
  14. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995